NovaMedica to invest $15 million in new R&D centre

18 December 2015

CeSports.EU

The Russian pharmaceutical company, NovaMedica, has announced plans to build a new research and development centre at Technopolis Moscow.  The new site will include laboratories with brand new state-of-the-art equipment and will allow the company to run up to fifteen projects each year and means that they will be able to produce approximately 75 million doses per year thanks to the production areas. Some of the equipment has never been used in the Russian pharmaceutical industry before. The centre will create 35 jobs and will take up around 1500 square metres of space.  

NovaMedica’s Vice President of Pharmaceutical Operations, Mikhail Getman has said “We are focusing on the development of innovative drug forms that provide controlled API bioavailability or combine previously incompatible APIs. Thereby, the developed products will have new potential applications and will be much better efficacy and safety than many current products. NovaMedica is the first company on this way forward”.

CEO of RMI Partners (managing company of Nova Medica), Vladimir Gurdus has said of the investment “Creation of a modern R&D centre is an important input into development of R&D industry and a link in the chain of input substitution process in any high-tech industry. Moreover, all innovative developments of NovaMedica will have patentable IP potential on a global level; we are planning to commercialize them not only in Russia but abroad as well”.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more